Home First Finance Company India Limited reported a 26.3% year-over-year increase in Assets Under Management (AUM), reaching ₹14,178 crores. The company continues to broaden its distribution footprint and sees strength in digital adoption, with 83% of approvals facilitated via the account aggregator framework. While delinquencies saw a slight uptick, the company anticipates improvements and is focused on maintaining healthy asset quality metrics.

Financial Performance Highlights

Home First Finance Company India Limited announced its Q2 FY26 results, showcasing strong growth and continued strategic expansion:

• AUM Growth: Increased by 26.3% year-over-year and 5.2% quarter-over-quarter, reaching ₹14,178 crores.
• Total Income: Rose to ₹479 crores, reflecting a 28% year-over-year increase and 5.2% quarter-over-quarter growth.
• Profit After Tax: Increased to ₹132 crores, a 43% year-over-year and 10.9% quarter-over-quarter increase.
• Net Interest Margin (NIM): Improved to 5.4% in Q2, up from 5.2% in the previous quarter.

Strategic Expansion and Digital Adoption

Home First continues to strategically expand its distribution network and strengthen its digital capabilities:

• The company has expanded its reach from 249 to 366 touchpoints over the last three years, marking a 47% increase.
• Branch Count: Increased from 101 to 163 branches.
• Digital Approvals: 83% of approvals in Q2 were facilitated via the account aggregator framework.
• Digital Loan Fulfillment: Over 80% of loans are digitally fulfilled through e-agreements and e-NACH mandates.
• Mobile App Adoption: 96% of customers registered on the mobile app, with 87% of service requests now raised digitally.

Asset Quality and Provisions

Home First is closely monitoring asset quality and maintaining a conservative approach to provisioning:

• 1+ DPD: Stood at 5.5%.
• 30+ DPD: Stood at 3.7%.
• Gross Stage 3: Stood at 1.9%.
• Provision Coverage: Total provision coverage is 40.8%.
• Credit Cost: 40 bps for Q2.

Capital Adequacy and Funding

• Capital to Risk-Weighted Assets Ratio: Stood at 48.4% as of September 2025.
• Net Worth: Increased to ₹4,014 crores, a 75% year-over-year increase.
• Book Value per Share: ₹388 as of September 2025.

Source: BSE

Lupin Limited announced its Bioresearch Center in Pune received zero observations from the U.S. Food and Drug Administration (FDA) following a clinical inspection from November 3 to November 6, 2025. A bio-analytical Remote Regulatory Assessment from October 30 to November 7, 2025, also concluded with no observations. This outcome highlights Lupin’s commitment to quality and compliance in its research facilities.

FDA Inspection Outcome

Lupin Limited (Lupin) announced that the United States Food and Drug Administration (U.S. FDA) has completed an onsite clinical inspection at its Bioresearch Centre in Pune. The inspection, conducted from November 3 to November 6, 2025, concluded with zero 483 observations.

Bio-analytical Assessment

Prior to the onsite inspection, a bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025. This assessment similarly concluded with no observations.

Management Commentary

Nilesh Gupta, Managing Director, Lupin, stated, “The successful outcome of the onsite clinical inspection and bio-analytical assessment by the U.S. FDA at our Bioresearch Centre is testament to our ongoing commitment to quality and compliance. We remain focused on improving the lives of our patients globally.”

About Lupin

Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India, with products distributed in over 100 markets. The company specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals.

Source: BSE

Blue Jet Healthcare reported robust earnings for Q2 FY’26, with EBITDA at Rs. 601 million (36% margin) and PAT at Rs. 432 million. H1 EBITDA reached Rs. 1,820 million (35% margin), and PAT was Rs. 1,342 million. The company is expanding capacity in Vizag for contrast media and artificial sweeteners, and backward integration in Mahad is on track. A new sweetener with a global market size of Rs. 1 billion is also in development.

Financial Highlights

Blue Jet Healthcare showcased a strong financial performance in Q2 FY’26 and H1 FY’26:

• Q2 FY’26:
  • EBITDA: Rs. 601 million (36% margin), up 14% year-on-year.
  • PAT: Rs. 432 million (26%).
• H1 FY’26:
  • EBITDA: Rs. 1,820 million (35%), up 41% year-on-year.
  • PAT: Rs. 1,342 million (36% growth).

Segment Performance

Contrast Media

Q2 revenues were Rs. 810 million, down 17% quarter-on-quarter. H1 revenues reached Rs. 1,780 million, consistent with the previous year. A new iodinated intermediate is expected to be commercial in Q4.

Pharma Intermediates and API

Q2 revenue was Rs. 420 million, down 80% quarter-on-quarter. However, H1 revenue grew by 113% year-on-year to Rs. 2,550 million. High-intensity Sweeteners grew 7% sequentially in Q2. A new Sweetener development has been approved with a global market size of Rs. 1 billion.

Strategic and Operational Updates

The groundwork has commenced on the 103-acre Vizag site, with Phase-I targeting capacity for contrast media and Artificial Sweeteners. The backward integration facility in Mahad is on track for commissioning by H2 FY’26.

Expansion Plans

The company has acquired a 103-acre land in Vizag and plans to add 1,000 KL capacity in the next 2-3 years. Phase-I, with a CAPEX of approximately Rs. 1,000 crores, includes blocks for Contrast Media, high-intensity Sweetener, and a multipurpose block. Phase-I is expected to be completed by FY’28.

R&D and Innovation

Blue Jet Healthcare is building capacity to supply building blocks and peptide fragments. A multipurpose plant and a state-of-the-art R&D center are planned in Hyderabad. The company is tracking 20 RFPs, including high conviction Phase-III leads in the chronic space. A new state-of-the-art R&D center is being planned at a cost of about Rs. 40 crores.

Sustainability

The company contributes about 70% of its total energy consumption from renewables and has received the CII National Award for Excellence in Energy Management.

Source: BSE